Evalution of Programmed Cell Death 4 (PDCD4) Expression in Patients with Acute Myeloid Leukemia

Document Type : Original Article (s)

Authors

1 MSc Student, Department of Hematology, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran

2 Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran

3 Professor, Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran

4 Associate Professor, Department of Hematology, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Acute myeloid leukemia (AML) is clinically, cytogenetically, and molecularly heterogeneous. Advances in molecular research have greatly improved our understanding of the leukemogenesis in AML. Programmed cell death-4 (PDCD4) is a novel tumor suppressor that inhibits neoplastic transformation and tumor progression and invasion by suppressing activator protein (AP)-1 activation and protein translation. In the present study, we examined the PDCD4 expression levels in de novo AML and investigated correlation between altered expression of PDCD4 with patients’ clinical characteristics.Methods: Peripheral blood samples were collected from 56 patients with AML at the time of diagnosis and also, 10 healthy individuals. Quantification of PDCD4 mRNA expression by Real Time Quantitative PCR was performed. Mann-Whitney U test was used to compare PDCD4 expression differences among healthy and AML samples.Findings: PDCD4 mRNA expression was significantly diminished in patients with AML at diagnosis in comparison to the PB as normal samples (P < 0.001). We observed a statistically lower expression in AML-M5 subtype in comparison to other AML subtypes (P = 0.028) .We have not found any significant correlation between PDCD4 expression level and clinical parameters of patients. Also, no significant correlation between the expression levels of PDCD4 and complete remission after induction therapy was observed.Conclusion: Our results shown that, like many epithelial cancers, the down-regulation of PDCD4 expression also occurs in AML.

Keywords

References

  1. Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program 2004; 80-97.
  2. Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011; 29(5): 475-86.
  3. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB.Cancer incidence in five continents. Volume VIII. IARC Sci Publ 2002; (155): 1-781.
  4. Zhang H, Ozaki I, Mizuta T, Hamajima H, Yasutake T, Eguchi Y, et al. Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma. Oncogene 2006; 25(45): 6101-12.
  5. Soejima H, Miyoshi O, Yoshinaga H, Masaki Z, Ozaki I, Kajiwara S, et al. Assignment of the programmed cell death 4 gene (PDCD4) to human chromosome band 10q24 by in situ hybridization. Cytogenet Cell Genet 1999; 87(1-2): 113-4.
  6. Lankat-Buttgereit B, Goke R. The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biol Cell 2009; 101(6): 309-17.
  7. Cmarik JL, Min H, Hegamyer G, Zhan S, Kulesz-Martin M, Yoshinaga H, et al. Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci U S A 1999; 96(24): 14037-42.
  8. Wei N, Liu SS, Chan KK, Ngan HY. Tumour suppressive function and modulation of programmed cell death 4 (PDCD4) in ovarian cancer. PLoS One 2012; 7(1): e30311.
  9. Wang Q, Sun Z, Yang HS. Downregulation of tumor suppressor Pdcd4 promotes invasion and activates both beta-catenin/Tcf and AP-1-dependent transcription in colon carcinoma cells. Oncogene 2008; 27(11): 1527-35.
  10. Leupold JH, Yang HS, Colburn NH, Asangani I, Post S, Allgayer H. Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors. Oncogene 2007; 26(31): 4550-62.
  11. Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S, et al. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol 2003; 23(1): 26-37.
  12. Chen Y, Knosel T, Kristiansen G, Pietas A, Garber ME, Matsuhashi S, et al. Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol 2003; 200(5): 640-6.
  13. Afonja O, Juste D, Das S, Matsuhashi S, Samuels HH. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis. Oncogene 2004; 23(49): 8135-45.
  14. Wei ZT, Zhang X, Wang XY, Gao F, Zhou CJ, Zhu FL, et al. PDCD4 inhibits the malignant phenotype of ovarian cancer cells. Cancer Sci 2009; 100(8): 1408-13.
  15. Gao F, Zhang P, Zhou C, Li J, Wang Q, Zhu F, et al. Frequent loss of PDCD4 expression in human glioma: possible role in the tumorigenesis of glioma. Oncol Rep 2007; 17(1): 123-8.
  16. Birg F, Courcoul M, Rosnet O, Bardin F, Pebusque MJ, Marchetto S, et al. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood 1992; 80(10): 2584-93.
  17. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352(3): 254-66.
  18. Ahuja HG, Foti A, Bar-Eli M, Cline MJ. The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood 1990; 75(8): 1684-90.
  19. Mori N, Hidai H, Yokota J, Okada M, Motoji T, Oshimi K, et al. Mutations of the p53 gene in myelodysplastic syndrome and overt leukemia. Leuk Res 1995; 19(11): 869-75.
  20. Ding L, Zhang X, Zhao M, Qu Z, Huang S, Dong M, et al. An essential role of PDCD4 in progression and malignant proliferation of gastrointestinal stromal tumors. Med Oncol 2012; 29(3): 1758-64.
  21. Ozpolat B, Akar U, Steiner M, Zorrilla-Calancha I, Tirado-Gomez M, Colburn N, et al. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res 2007; 5(1): 95-108.
  22. Yoshinaga H, Matsuhashi S, Fujiyama C, Masaki Z. Novel human PDCD4 (H731) gene expressed in proliferative cells is expressed in the small duct epithelial cells of the breast as revealed by an anti-H731 antibody. Pathol Int 1999; 49(12): 1067-77.
  23. Wang X, Wei Z, Gao F, Zhang X, Zhou C, Zhu F, et al. Expression and prognostic significance of PDCD4 in human epithelial ovarian carcinoma. Anticancer Res 2008; 28(5B): 2991-6.
  24. Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W. Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 2004; 50(3): 197-222.
Journal of Isfahan Medical School
Volume 31, Issue 241 - Serial Number 241
May and June 2013
Pages 867-875

Files

History

  • Receive Date: 02 April 2013
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics